Singapore, April 3 -- Transgene, a French biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of Japan's NEC Corporation, a leader in IT, network and AI technologies, have announced the signing of a license agreement to advance the clinical development of TG4050, an individualised neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.TG4050 is an individualised immunotherapy based on an MVA viral vector incorporating neoantigens selected using NEC's AI-enabled prediction platform. 

It is currently being evaluated in patients with head and neck cancer with the aim of preventing r...